We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarkers Identified for Early Lung Cancer Diagnosis

By LabMedica International staff writers
Posted on 01 Sep 2015
Print article
Image: The Agilent 1200 high-performance liquid chromatography system (Photo courtesy of Marine Biophysics Laboratory).
Image: The Agilent 1200 high-performance liquid chromatography system (Photo courtesy of Marine Biophysics Laboratory).
Lung cancer can be diagnosed early with regular low-dose computed tomography (CT) scans of people at risk, but these tests are very expensive, and also involve exposing patients to X-ray radiation.

Patients are often diagnosed with lung cancer only when their disease is already at an advanced stage and hard to treat, so medical professionals are trying to change that, by identifying biomarkers that could be the basis of early tests for lung cancer.

Scientists at the West Coast Metabolomics Center (Davis, CA, USA) analyzed blood samples collected from people who developed the disease, months or years before they were diagnosed. They were able to access samples stored from the Beta-Carotene and Retinol Efficacy Trial (CARET) clinical trial. A liquid chromatography/mass spectrometry hydrophilic interaction method designed to profile a wide range of metabolites was applied to pre-diagnostic serum samples from CARET participants who were current or former heavy smokers, consisting of 100 patients who subsequently developed non-small-cell lung cancer (NSCLC) and 199 matched controls.

The team used the Agilent 1200 high-performance liquid chromatography system and the Agilent quadrupole time-of-flight (QTOF) 6530 mass spectrometer (Agilent Technologies; Santa Clara, CA, USA) with a JetStream ion source. A separate serum aliquot was used to quantify levels of pro-surfactant protein B (pro-SFTPB), a previously established protein biomarker for NSCLC. A blinded validation of a metabolite, identified as N1,N12-diacetylspermine (DAS), and pro-SFTPB was performed using an independent set of CARET pre-diagnostic sera from 108 patients with NSCLC and 216 matched controls. Serum DAS was elevated by 1.9-fold, demonstrating significant specificity and sensitivity in the discovery set for samples collected up to six months before diagnosis of NSCLC. In addition, DAS significantly complemented performance of pro-SFTPB in both the discovery and validations sets.

Oliver Fiehn, PhD, a professor of molecular and cellular biology, and senior author of the study, said, “Early diagnosis is the key to fighting lung cancer. Individually, the markers diacetylspermine and pro-surfactant protein B were about 70% predictive, but in combination, that rose to 80%. In other words, eight out of ten people with early-stage cancer would be correctly identified by the combined test.” The study was published on August 17, 2015, in the Journal of Clinical Oncology.

Related Links:

West Coast Metabolomics Center
Agilent Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.